J Adv Pract Oncol. 2019 Aug;10(6):576-583. doi: 10.6004/jadpro.2019.10.6.7. Epub 2019 Aug 1.
Options for patients with non-small cell lung cancer have expanded following trials studying the safety and efficacy of checkpoint inhibitors and targeted therapies. of MD Anderson Cancer Center reviews the major abstracts from the 2019 ASCO Annual Meeting using coverage by and offers considerations for advanced practitioners in this field.
在对检查点抑制剂和靶向疗法的安全性和有效性进行研究的试验之后,非小细胞肺癌患者的治疗选择有所增加。MD安德森癌症中心的[具体人员或团队]使用[具体来源或方式]对2019年美国临床肿瘤学会年会的主要摘要进行了综述,并为该领域的高级从业者提供了一些思考。